{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"Number of patients that are alive without recurrence when recurrence is defined by any subject with new evidence of cancer after achieving a complete response. Complete response is defined by the complete disappearance of all clinically and radiologically detectable tumor..","groups":[{"description":"Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.","id":"OG000","title":"Arm A"},{"description":"Patients undergo radiotherapy as in arm I and receive fluorouracil IV and cisplatin IV continuously on days 1-4 and 22-25 of radiotherapy.","id":"OG001","title":"Arm B"}],"paramType":"NUMBER","populationDescription":"intention to treat (ITT)","reportingStatus":"POSTED","timeFrame":"at 2 yrs from start of study","title":"Relapse Free Survival","type":"PRIMARY","unitOfMeasure":"participants"}